GFAP Antibody (GFAP/8615R) - Azide and BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-24135
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Rabbit IgG Kappa Clone # GFAP/8615R
Format
Azide and BSA Free
Concentration
1 mg/ml
Product Summary for GFAP Antibody (GFAP/8615R) - Azide and BSA Free
Immunogen
Recombinant fragment (around aa150-350) of human GFAP protein (exact sequence is proprietary)
Localization
Cytoplasm.
Specificity
This monoclonal antibody recognizes a protein of ~50kDa which is identified as Glial Fibrillary Acidic Protein (GFAP). It shows no cross-reaction with other intermediate filament proteins.
Marker
Astrocyte & Neural Stem Cell Marker
Clonality
Monoclonal
Host
Rabbit
Isotype
IgG Kappa
Description
Antibody without azide - store at -20 to -80C.
Applications for GFAP Antibody (GFAP/8615R) - Azide and BSA Free
Application
Recommended Usage
Immunohistochemistry-Paraffin
1-2ug/ml
Application Notes
Immunohistochemistry-Paraffin: 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95C followed by cooling at RT for 20 minutes. Optimal dilution for a specific application should be determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10mM PBS
Format
Azide and BSA Free
Preservative
No Preservative
Concentration
1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at -20 to -80C. Avoid freeze-thaw cycles.
Background: GFAP
An increase in GFAP levels is often associated with neuroinflammation which results in the activation and proliferation of astroglia cell population (1,2). GFAP expression is also observed in brains of patients with neurodegenerative diseases including Alzheimer's and Parkinson's, epilepsy disorders, and brain injuries (1-4). Lesion sites associated with neurodegeneration can exhibit an array of gliosis characteristics from glial scarring with reduced astrocyte proliferation to activated, GFAP-positive astrocytes surrounding amyloid plaques (2). Furthermore, the GFAP gene is a target of single nucleotide polymorphisms in the coding region, considered a gain-of-function mutation, characterized by astrocytic inclusions, termed Rosenthal fibers, resulting in Alexander Disease (1-4). GFAP is also a center of many post-translational modifications, such as phosphorylation, which can alter various aspects of filament assembly (1,4).
References
1. Yang, Z., & Wang, K. K. (2015). Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends in Neurosciences. https://doi.org/10.1016/j.tins.2015.04.003
2. Hol, E. M., & Capetanaki, Y. (2017). Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin. Cold Spring Harbor Perspectives in Biology. https://doi.org/10.1101/cshperspect.a021642
3. Potokar, M., Morita, M., Wiche, G., & Jorgacevski, J. (2020). The Diversity of Intermediate Filaments in Astrocytes. Cells. https://doi.org/10.3390/cells9071604
4. Viedma-Poyatos, a., Pajares, M. A., & Perez-Sala, D. (2020). Type III intermediate filaments as targets and effectors of electrophiles and oxidants. Redox Biology. https://doi.org/10.1016/j.redox.2020.101582
Long Name
Glial Fibrillary Acidic Protein
Alternate Names
ALXDRD, FLJ45472, GFAP, GFAP astrocytes, glial fibrillary acidic protein
Gene Symbol
GFAP
Additional GFAP Products
Product Documents for GFAP Antibody (GFAP/8615R) - Azide and BSA Free
Product Specific Notices for GFAP Antibody (GFAP/8615R) - Azide and BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...